课题基金 / 基金详情

Development of novel immunogene therapy for hematological malignancies

Development of novel immunogene therapy for hematological malignancies
血液系统恶性肿瘤新型免疫基因疗法的开发
批准号:
12557081
负责人:
YASUKAWA Masaki
金额:
$7.68万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

YASUKAWA Masaki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study was performed to develop the novel immunotherapy for hematological malignancies. The data obtained from the series of experiments are as follows.1) A novel WT1-derived peptide-specific CD8^+ CTL line, designated NIM-1 was established. NIM-1 lysed HLA-A24-positive leukaemia cells, but not HLA-A24-negative leukaemia cells or normal cells.2) A WT1-specific, HLA-A24-restricted CTL clone (designated TAK-1) exhibited cytotoxicity against lung cancer cell lines bearing HLA-A24 but did not lyse cells lacking this HLA. Adoptive transfer of TAK-1 into nude mice that had been engrafted with an HLA-A24-positive lung cancer cell line resulted in inhibition of the cancer cell growth and prolonged survival. These findings strongly suggest that WT1 is a universal tumor-associated antigen and that WT1 -targeting immunotherapy offers a potentially effective treatment option for lung cancer as well as leukemia.3) Immature dendritic cells (DCs) were loaded with leukemia cells with t(6 ; 9) or t … More (9 ; 22) and then cocultured with the dek-can fusion peptide-specific or the bcr abl fusion peptide-specific CD4^+ T-lymphocyte clone. The dek-can peptide-specific and bcr-abl peptide-specific CD4^+ T-lymphocyte clones produced interferon-γ (IFN-γ) when they were cocultured with HLA-DR-matched but not with mismatched DCs which had been loaded with apoptotic as well as necrotic leukemia cells with t(6 ; 9) and t(9 ; 22), respectively. These data indicate that the acute myelogenous leukemia-associated fusion protein, dek-can and chronic myelogenous leukemia-associated fusion protein, bcr-abl, are both processed and presented by DCs to the fusion peptide-specific CD4^+ T lymphocytes.4) In order to clarify the roles of perform in antigen-specific cytotoxicity mediated by human CD4^+ CTLs, antigen-specific human CD4^+ T-lymphocyte clones were established from a patient with hereditary perforin deficiency and their cytotoxic activities were investigated. The data demonstrated that perforin-negative CD4^+ CTLs can exert cytotoxicity against Fas-sensitive target cells ; however, perforin plays essential roles in antigen-specific cytotoxicity mediated by human CD4^+ as well as CD8^+ CTLs. Less
期刊论文(64)
专著(0)
科研奖励(0)
会议论文
Azuma, T., et al.: "Identification of a novel WT1-derived peptide which induces HLA-A24-restricted anti-leukaemia cytotoxic T lymphocytes"British Journal of Haematology. 116. 601-603 (2002)
Azuma,T.,等人:“诱导 HLA-A24 限制性抗白血病细胞毒性 T 淋巴细胞的新型 WT1 衍生肽的鉴定”英国血液学杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yasukawa M., et al: "Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia"American Journal of Hematology. 63. 99-101 (2000)
Yasukawa M.等人:“日本慢性粒细胞白血病患者的HLA-DRB1等位基因分析”美国血液学杂志。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Hamada, M., Yakushijin, Y., Watanabe, L., Kakimoto, M., Yasukawa, M. and Fujita, S.: "Aurora2/BTAK/STKI5 is involved in cell-cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma"Br.J.Haematol.. (in press).
Hamada, M.、Yakushijin, Y.、Watanabe, L.、Kakimoto, M.、Yasukawa, M. 和 Fujita, S.:“Aurora2/BTAK/STKI5 参与侵袭性非-细胞周期检查点和细胞存活。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kakimoto, M., Hasegawa, A., Fujita, S. and Yasukawa, M.: "Phenotypic and functional alterations of dendritic cells induced by human herpesvirus 6 infection"J.Virol.. 76. 10338-10345 (2002)
Kakimoto, M.、Hasekawa, A.、Fujita, S. 和 Yasukawa, M.:“人疱疹病毒 6 感染诱导的树突状细胞的表型和功能改变”J.Virol.. 76. 10338-10345 (2002)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
28
    Development of the novel gene-immunotherapy using artificial CTL targeting leukemia stem cells
    • 批准号:
      24390245
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.4万
    • 财政年份:
      2012
    • 负责人:
      YASUKAWA Masaki
    • 依托单位:
    Development of a novel cancer therapy using soluble T-cell receptor
    • 批准号:
      23659489
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2011
    • 负责人:
      YASUKAWA Masaki
    • 依托单位:
    Development of cancer immunotherapy using co-transfer of cancer-specific TCR gene and chemokine receptor gene
    • 批准号:
      21390294
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.48万
    • 财政年份:
      2009
    • 负责人:
      YASUKAWA Masaki
    • 依托单位:
    Novel hematopoietic stem cell transplantation using cancer-specific T-cell receptor gene transfer
    • 批准号:
      19390265
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.81万
    • 财政年份:
      2007
    • 负责人:
      YASUKAWA Masaki
    • 依托单位:
    海外基金